Metraipolis › archive › dc_617d28ecea10

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study — Europe PMC PMID:41929598

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41929598
DOI
10.3389/fneur.2026.1783506
License (as archived)
solo-consultazione
Archived
2026-11-04T07:41:39.109Z
SHA-256 of the archived text
ac975dbdeb9163cdf1e265b81c2ddd2165750166d380742bd9ed22626dece4f2
Stable URL of this page
https://metraipolis.com/documento/dc_617d28ecea10

How to cite

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study — Europe PMC PMID:41929598 — Europe PMC (en), https://europepmc.org/article/MED/41929598 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_617d28ecea10 (Metraipolis archive dc_617d28ecea10, sha256 ac975dbdeb9163cdf1e265b81c2ddd2165750166d380742bd9ed22626dece4f2)
BibTeX
@misc{dc617d28ecea10,
  title = {Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study — Europe PMC PMID:41929598},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41929598},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_617d28ecea10; sha256 ac975dbdeb9163cdf1e265b81c2ddd2165750166d380742bd9ed22626dece4f2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41929598. Agents can read the archived copy with the MCP tool read_document.